Q2 2025 Solara Active Pharma Sciences Ltd Earnings Call Transcript
Key Points
- Solara Active Pharma Sciences Ltd (BOM:541540) achieved a gross margin of 50.5%, marking a historical high with a 620 basis point improvement year-on-year.
- The company's EBITDA grew by 46% quarter-on-quarter and 61% year-on-year, reflecting a strong financial recovery.
- Revenues from regulated markets now constitute 76% of the business, indicating a strategic focus on stable and profitable markets.
- The company has successfully reduced operational costs significantly without compromising on quality compliance.
- Solara Active Pharma Sciences Ltd (BOM:541540) has received significant quality approvals for its plants and R&D center, enhancing its operational credibility.
- The company is still in the process of retrofitting its Vizag plant, which has impacted capacity utilization.
- There is a dependency on Ibuprofen, which constitutes 25% of the company's global revenues, posing a risk if market dynamics change.
- The CRAMS business, while growing, is still suboptimal and contributes less than INR100 crores annually.
- The company has a significant amount of debt, with plans to become net cash positive only by FY27.
- Solara Active Pharma Sciences Ltd (BOM:541540) is not focusing on filing many new DMFs, which could limit future growth opportunities.
Ladies and gentlemen, good day, and welcome to Solara Active Pharma Sciences Limited Q2 and H1 FY25 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Abhishek. Thank you, and over to you, sir.
Very good afternoon to all of you and thank you for joining us today for Solara Active Pharma Sciences earnings conference call for the second quarter and half year ended FY2025.
Today, we have with us Arun, Solara's Founder and Non-Executive Director; Poorvank Purohit, MD and CEO; and Arun Kumar Baskaran, CFO, to share the highlights of the business and financials for the quarter.
I hope you've gone to our reserve release and the quarterly investor presentation, which have been uploaded on our website as well as the stock exchange website. The transcript for this call will be available in a week's time on company's website.
Please note that today's discussion may be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
